Metropolis Healthcare reports Q1 FY26 PAT higher by 19% at Rs. 45 Cr

Vertex faces regulatory delays for Journavx and reports VX-993 Phase 2 trial failure

Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint

Sanofi Consumer Healthcare India reports Q2 2025 PAT at Rs. 60.7 Cr

The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore

GlaxoSmithKline Pharmaceuticals reports Q1 FY26 PAT at Rs. 205 Cr

The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results

Ajanta Pharma reports Q1 FY26 consolidated PAT at Rs. 255.34 Cr

Ajanta Pharma has reported total income of Rs. 1,328.98 crores during the period ended June 30, 2025

Vijaya Diagnostic reports Q1 FY26 consolidated PAT at Rs. 38.33 Cr

The company would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal

Piramal Pharma reports Q1 FY26 consolidated loss at Rs. 81.70 Cr

Piramal Pharma has reported total income of Rs. 1,992.11 crores during the period ended June 30, 2025

Sigachi Industries reports Q1 FY26 consolidated loss at Rs. 100.35 Cr

Sigachi Industries has reported total income of Rs. 132.18 crores during the period ended June 30, 2025

Cipla reports Q1 FY2025-26 consolidated profit up at Rs. 1,297.62 Cr

Cipla has reported total income of Rs. 7,216.03 crores during the period ended June 30, 2025

Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs. 1,418 Cr

Revenue increased 11.4 per cent to Rs. 8,545 crore